Catalent Revenue 2012-2022 | CTLT

Catalent annual/quarterly revenue history and growth rate from 2012 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Catalent revenue for the quarter ending March 31, 2022 was $1.273B, a 20.89% increase year-over-year.
  • Catalent revenue for the twelve months ending March 31, 2022 was $4.703B, a 25.17% increase year-over-year.
  • Catalent annual revenue for 2021 was $3.998B, a 29.22% increase from 2020.
  • Catalent annual revenue for 2020 was $3.094B, a 22.88% increase from 2019.
  • Catalent annual revenue for 2019 was $2.518B, a 2.22% increase from 2018.
Catalent Annual Revenue
(Millions of US $)
2021 $3,998
2020 $3,094
2019 $2,518
2018 $2,463
2017 $2,075
2016 $1,848
2015 $1,831
2014 $1,828
2013 $1,800
2012 $1,695
2011 $1,532
Catalent Quarterly Revenue
(Millions of US $)
2022-03-31 $1,273
2021-12-31 $1,217
2021-09-30 $1,025
2021-06-30 $1,188
2021-03-31 $1,053
2020-12-31 $911
2020-09-30 $846
2020-06-30 $947
2020-03-31 $761
2019-12-31 $721
2019-09-30 $665
2019-06-30 $726
2019-03-31 $618
2018-12-31 $623
2018-09-30 $552
2018-06-30 $685
2018-03-31 $628
2017-12-31 $606
2017-09-30 $544
2017-06-30 $617
2017-03-31 $533
2016-12-31 $484
2016-09-30 $442
2016-06-30 $532
2016-03-31 $438
2015-12-31 $455
2015-09-30 $423
2015-06-30 $510
2015-03-31 $447
2014-12-31 $456
2014-09-30 $418
2014-06-30 $520
2014-03-31 $453
2013-12-31 $441
2013-09-30 $414
2013-06-30
2013-03-31
2012-06-30
2011-06-30
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $17.531B $3.998B
Catalent, Inc. is a renowned global provider of advanced delivery technologies as well as development and manufacturing solutions for drugs (protein, cell, and gene therapy biologics) and consumer health products.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $74.764B 33.37
Takeda Pharmaceutical (TAK) Japan $44.809B 7.53
Stevanato Group S.p.A (STVN) Italy $4.631B 29.02
Taro Pharmaceutical Industries (TARO) Israel $1.402B 11.44
USANA Health Sciences (USNA) United States $1.333B 12.85
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.054B 5.12
Rafael Holdings (RFL) United States $0.038B 0.00
Lannett Co Inc (LCI) United States $0.023B 0.00